Managing Adverse Events in Patients Utilizing Antibody–Drug Conjugate Therapy

This article will highlight common and serious adverse events (AEs) to be aware of when treating patients with antibody–drug conjugate therapy, as well as provide commentary from Tajuana Bradley, MS, FNP-BC, on key points of intervention when resolving these AEs and supporting patients through the treatment journey.

This article explores the pharmacist’s vital role in mitigating adverse events, enhancing patient adherence, and optimizing therapeutic outcomes in patients being treated with antibody–drug conjugate therapies.